Delivering Precision Oncology at Scale-Infrastructure, Evidence, and the Path Forward [0.03%]
大规模精准肿瘤学的实施、证据和前进之路：基础设施
Vivek Subbiah
Vivek Subbiah
Implementing Cancer Medicines on the WHO Model Lists of Essential Medicines Into National Systems [0.03%]
世卫组织基本药物示范名录的肿瘤药品落地国家药政体系项目
Kristina Jenei,Richard Sullivan
Kristina Jenei
Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial [0.03%]
_upadacitinib治疗免疫检查点抑制剂相关皮炎的疗效：一项非随机临床试验
Chengshui Chen,Xinyu Liang,Zheng Peng et al.
Chengshui Chen et al.
Delphine Maret,Joel B Epstein,Emmanuelle Vigarios
Delphine Maret
Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial [0.03%]
一项关于老年晚期癌症患者的预后分析：选择生活质量的患者与选择延长生存期的患者相比如何？基于GAP70+群组随机临床试验的二次分析
Daniel R Richardson,Ying Wang,Marie Flannery et al.
Daniel R Richardson et al.
Importance: Health care systems should strive to achieve outcomes that matter to patients. Limited data exist on the outcomes achieved by patients with cancer with different treatment outcome preferences. ...
Frank P Lin,Subotheni Thavaneswaran,John P Grady et al.
Frank P Lin et al.
Importance: The clinical utility of matching therapies to genomic biomarkers based on varying levels of evidence remains uncertain, particularly for patients with rare and refractory cancers. ...
Nancy L Keating,Lydia E Pace
Nancy L Keating
Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations [0.03%]
KIT第9外显子突变胃肠道间质瘤患者的辅助伊马替尼治疗与观察随访对比研究
Andrea Napolitano,Heikki Joensuu,Sara Rothschild et al.
Andrea Napolitano et al.
Importance: Gastrointestinal stromal tumors (GISTs) harboring KIT exon 9 mutations represent a biologically distinct subgroup with reduced sensitivity to standard-dose imatinib in the advanced setting. The benefit of adju...
First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial [0.03%]
替雷利珠单抗联合化疗一线治疗复发或转移性鼻咽癌：RATIONALE 309 随机临床试验的三年随访结果
Yunpeng Yang,Chia-Jui Yen,Jianji Pan et al.
Yunpeng Yang et al.
Importance: Nasopharyngeal carcinoma (NPC) is a major health concern in Asia, and treatment options for recurrent or metastatic disease are limited. Immunotherapy plus chemotherapy has shown promise, but long-term data ar...